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ABSTRACT: Jay Amin hydroxamic acid (JAHA; N8-
ferrocenylN1-hydroxy-octanediamide) is a ferrocene-contain-
ing analogue of the histone deacetylase inhibitor (HDACi)
suberoylanilide hydroxamic acid (SAHA). JAHA’s cytotoxic
activity on MDA-MB231 triple negative breast cancer
(TNBC) cells at 72 h has been previously demonstrated
with an IC50 of 8.45 μM. JAHA’s lethal eﬀect was found linked
to perturbations of cell cycle, mitochondrial activity, signal
transduction, and autophagy mechanisms. To glean novel
insights on how MDA-MB231 breast cancer cells respond to
the cytotoxic eﬀect induced by JAHA, and to compare the
biological eﬀect with the related compound SAHA, we have employed a combination of diﬀerential display-PCR, proteome
analysis, and COMET assay techniques and shown some diﬀerences in the molecular signature proﬁles induced by exposure to
either HDACis. In particular, in contrast to the more numerous and diversiﬁed changes induced by SAHA, JAHA has shown a
more selective impact on expression of molecular signatures involved in antioxidant activity and DNA repair. Besides expanding
the biological knowledge of the eﬀect exerted by the modiﬁcations in compound structures on cell phenotype, the molecular
elements put in evidence in our study may provide promising targets for therapeutic interventions on TNBCs.
■ INTRODUCTION
Histone deacetylase inhibitors (HDACis) are chemically
heterogeneous promising anticancer agents that restore a
relaxed, hyperacetylated chromatin structure and potentially
lead to re-expression of silenced genes or silencing of
downstream genes, ultimately inducing death, apoptosis, and
cell cycle arrest in cancer cells also via non histone-targeted
mechanisms such as perturbations of p53, cytokine signaling
pathways, and angiogenesis (e.g., ref 1). HDACis are grouped
into diﬀerent categories on the basis of their chemical nature,
and the consequence of this molecular diversity is that the
precise mechanism through which these compounds work is
still poorly understood.
Suberoylanilide hydroxamic acid (SAHA), that is, Vorinostat,
is a prototypical HDACi targeting class I and II HDAC
approved in 2006 by the Food and Drug Administration for
treatment of cutaneous T-cell lymphoma.2 A number of studies
have focused on the understanding of the biological properties
of the compound as an anticancer agent, especially against
tumors with intrinsic highly malignant potential. Triple-
negative breast cancer (TNBC) is a tumor histotype, which is
poorly responsive to hormonal therapies and to HER2-
targeting drugs and usually associated with worse prognosis
than other breast cancers. It is therefore very important to
develop and test novel drugs or analogues of pre-existing drugs
that counteract TNBC cell growth. In this context, drugs
targeting multiple signaling pathways and epigenetic drugs
appear to be the most promising.3 Exposure of TNBC MDA-
MB231 cells to SAHA was found to determine the modiﬁcation
of selected gene expression patterns, the disruption of
transduction signaling, and the onset of apoptosis.4−7
Several manipulations of the core structure of SAHA have
been carried out to probe the eﬀect of such SAR (structure
activity relationships) modiﬁcations on both HDAC inhibitory
activity and cytotoxic eﬀects on cancer cells (e.g., ref 8).
HDACis typically contain a cap (often aryl group), a linker, and
a zinc-binding group. Spencer et al.9 reported the synthesis of
metal-based SAHA analogues that contain a ferrocene cap that
are air stable and readily modiﬁable synthetically such as Jay
Amin hydroxamic acid (JAHA). If compared with parental
SAHA, JAHA displays similar broad inhibitory proﬁles toward
class I HDACs, including HDAC8, whereas it is inactive on
class IIa HDACs. Indeed, many studies have shown that the
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introduction of a ferrocene motif can lead to signiﬁcant changes
in bioactivity not only due to its size and shape, which may alter
interactions with crucial residues in active sites for example, but
also due to its potential for redox activity (Fe(II)/Fe(III) and
induction of reactive oxygen species.10−14
Given its diﬀerent structure, this new compound underwent
further study, and in a previous set of experimental assays its
ability to counteract TNBC MDA-MB231 cell growth and the
related biological aspects were tested. JAHA exhibited a
remarkable activity on cell viability and proliferation with an
IC50 of 8.45 μM at 72 h. In particular, JAHA’s cytotoxic activity
implied (i) cell cycle perturbation, likely related to an inability
of cells to proceed through the G2/M transition, (ii) an early
increase of reactive oxygen species production followed by
dissipation of mitochondrial transmembrane potential, and (iii)
the inhibition of the autophagic process that plays a pro-survival
role in this cell line. Noteworthy, JAHA did not induce the
onset of apoptosis that was instead promoted by the archetypal
SAHA at the same concentration.4 Contrary to JAHA, SAHA
was proven to enhance the autophagic process in diﬀerent
model systems (e.g., ref 15). Moreover, dealing with survival-
related signal transduction pathways, Librizzi et al.16 reported
that, diﬀerently from SAHA, JAHA induced the deactivation of
pERK1/2, leaving pAKT levels unaltered in MDA-MB231 cells.
The resulting inhibition of DNMT1 and DNMT3b methyl-
transferase activity resulted in a generalized DNA demethyla-
tion following JAHA treatment with consequent implications in
transcriptional regulation and gene expression pattern.
These cumulative results highlighted a modiﬁcation of the
biological eﬀect consequent to the manipulation of the original
molecular structure. It is widely acknowledged that the
characterization of the biological activity of new potential
anticancer compounds, such as ferrocene-based SAHA
analogues, is necessary to establish drug safety and eﬃcacy
proﬁles. In addition, information on the mode of action of the
diﬀerent HDACis may reveal new molecular targets of putative
applicative interest, which ultimately may be useful in the
design of more appropriate intervention and therapies for
tumors with inherent aggressive biology and limited treatment
options such as TNBCs. To get novel insight on how MDA-
MB231 breast cancer cells respond to the cytotoxic eﬀect
induced by JAHA, and to compare the biological eﬀect of the
related compounds JAHA and SAHA, we have employed a
combination of diﬀerential display-PCR, proteome analysis, and
Comet assay techniques and shown diﬀerent molecular
signature proﬁles induced by exposition to either HDACis.
As well as expanding the biological knowledge of the eﬀect
exerted by the modiﬁcations in compound structures on cell
phenotype, the molecular elements put in evidence in our study
may provide promising targets for therapeutic interventions on
TNBCs.
■ EXPERIMENTAL PROCEDURES
Cells and Treatments. MDA-MB231 breast tumor cells were
maintained in RPMI 1640 medium plus 10% fetal bovine serum, 100
U/mL penicillin, 100 μg/mL streptomycin, and 2.5 mg/L amphoter-
icin B (Invitrogen, Carlsbad, CA, USA), at 37 °C in a 5% CO2
atmosphere. The cells were detached from ﬂasks with 0.05% trypsin-
EDTA, counted, and plated at the necessary density for treatment after
achieving 60−80% conﬂuency. The HDACis SAHA and JAHA, the
latter synthesized as reported in Spencer at al.,9 were dissolved in
dimethyl sulfoxide as stock solutions. Cells (1 × 106) were plated in 75
cm2 ﬂasks and allowed to adhere overnight. Then the cells were
treated with either JAHA or SAHA at 8.45 μM concentration or with
the vehicle for 18, 24, and 48 h.
Messenger RNA Isolation and Reverse Transcription.
Isolation of total RNA from monolayers of trypsinized control and
HDACi-exposed cells and reverse transcriptase reaction were
performed with TRIzol reagent (Invitrogen) as described by Sirchia
and Luparello.17 Messenger RNA-enriched samples from total RNA
preparations were obtained using Terminator 5′-phosphate-dependent
exonuclease (Epicenter, Madison, WI, USA) following manufacturer’s
instructions, and the mRNA preparations were puriﬁed from excess
EDTA, tRNA, 5S rRNA, and other small RNA species by LiCl
precipitation. The cDNAs were synthesized from 250 ng of mRNA in
the presence of random hexamer primers using Superscript II reverse
transcriptase (Invitrogen), and their quality was checked by
ampliﬁcation of “housekeeping” β-actin cDNA.
Diﬀerential Display (DD) and Real Time-PCR. For diﬀerential
expression analysis, DD-PCR experiments were performed as already
reported (e.g., refs 18 and 19) using 25 pmol of the arbitrary 10-mer
primers designed by Sokolov and Prokop,20 in combinations of two,
and 3.6 U of AmpliTaq DNA polymerase, Stoﬀel fragment (Applied
Biosystems/Life Technologies, Carlsbad, CA, USA). The ampliﬁcation
products were checked by nondenaturing 6% polyacrylamide gel
electrophoresis (PAGE), performed in a Sequi-Gen sequencing
apparatus (Bio-Rad, Hercules, CA, USA) at constant 55 W, and silver
staining. The 50 bp DNA Ladder (Invitrogen) was run in parallel for
reference and the evaluation of band size performed with SigmaGel
software (SPSS, Blairgowrie, UK). The DD-bands of interest were
scratched from the gel and used as template for repeated cycles of
ampliﬁcation and electrophoresis until a single pure band was
visualized. Then the PCR products were ﬁrst puriﬁed using the
Montage PCR Centrifugal Filter Devices (Millipore, Billerica, MA,
USA) followed by treatment with ExoSAP-IT (USB, Cleveland, OH,
USA) to remove any unconsumed dNTPs and primers remaining in
the PCR product mixture, which could interfere with the sequencing
reaction. The puriﬁed PCR products were submitted for sequencing by
BMR Genomics (Padova, Italy) and DNA sequence similarity was
searched with the Nucleotide BLAST algorithm available online.
Messenger RNA expression levels were evaluated by quantitative
real-time PCR using Power SYBR Green PCR Master Mix (Applied
Biosystems, Philadelphia, PA, USA) as previously described21 in a
7300 Real Time PCR system (Applied Biosystems) in the presence of
2.5 μM of the primers listed in Table 1 and designed using the Primer3
software available at http://biotools.umassmed.edu/bioapps/primer3_
www.cgi. Either GAPDH or β-actin was used as internal control. The
PCR data obtained were automatically analyzed by the Relative
Quantiﬁcation Study Software (Applied Biosystem) and expressed as
target/reference ratio. Thermocycler conditions were 95 °C for 10
min, followed by 40 cycles of 95 °C for 1 min, and 60 °C for 1 min.
Liquid Chromatography−Tandem Mass Spectrometry (LC−
MS/MS). Trypsinized control and HDACi-treated cells were dissolved
in a solubilization buﬀer (0.1 M Tris-HCl, pH 8, 25 mM EGTA, 4%
SDS, 1X protease inhibitors cocktail, all purchased from Sigma). Then
the samples were sonicated, boiled for 3−5 min, and clariﬁed by
centrifugation for 15 min at maximum speed after which the
supernatant was collected. The proteins were precipitated using 5
volumes of cold acetone (−20 °C), centrifuged at 13 000 rpm for 10
min at 4 °C, and resuspended in 0.1% SDS before sonication. The
protein samples were quantiﬁed using the BCA assay kit (Thermo
Scientiﬁc), and 5 μg was used for tryptic digestion and protein
identiﬁcation for quantitative analysis, whereas 24 μg was used for
qualitative analysis. Mass spectrometry was performed as reported by
Rozek et al.22 Brieﬂy, the digested peptides were ﬁrst applied to a RP-
18 trapping column (nanoACQUITY UPLC Symmetry C18 Trap,
Waters, Milford, MA, USA) using 0.1% triﬂuoroacetic acid mobile
phase and then to a HPLC RP-18 column (nanoACQUITY UPLC
BEH C18 Column, Waters) using an acetonitrile gradient (0−30% in
0.1% formic acid), and the column outlet was directly coupled to the
ion source of the Ion Cyclotron Resonance spectrometer (LTQ61
FTICR, Thermo Electron). Each sample was submitted to triplicate
LC/MS runs followed by analysis on LTQ OrbitrapVelos (Thermo
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Scientiﬁc, San Jose, CA, USA). The following parameters for dynamic
exclusion were applied: 1 repeat count, 30 ms repeat duration, 500
exclusion list size, 120 s exclusion duration, exclusion width low energy
0.51; exclusion width high energy 1.51. The peptides identiﬁed in all
LC−MS/MS analyses were merged into a common list, which was
next overlaid onto 2-D maps generated from the LC/MS proﬁle data
of individual samples, as previously reported.23
Bioinformatic Analysis. The acquired raw data were processed to
produce peak lists by Mascot Distiller software (version 2.2.1, Matrix
Science, London, UK). The resulting ion lists were searched using the
Mascot search engine (version 2.2.03, Matrix Science) against a
database comprising all human protein entries from the Sprot and
their reversed versions. The search parameters were as follows:
enzyme speciﬁcity, trypsin; variable modiﬁcations, oxidation (M); and
protein mass, unrestricted. The peptide and fragment ion mass
tolerances used were 20 ppm and 0.6 Da, respectively. Peptides with
Mascot score exceeding the threshold value corresponding to <5%
false positive rate calculated by Mascot procedure were considered to
be positively identiﬁed. At least two peptides for each protein with a
score above the threshold were required for the identiﬁcation. The
qualitative analysis of protein/peptide lists generated by the Mascot
search engine was performed using MScan, whereas for quantitative
estimation the MSparky software tool was used. The statistical analysis
was performed using the DiﬀProt software, thereby obtaining a list of
diﬀerentially expressed proteins. For each of them the R (ratio) and F
(fold change) values were estimated to identify up-/down-regulation
and fold changing, respectively. Data are shown as mean ± s.e.m. of
independent triplicate experiments. The p values obtained were
corrected for multiple-hypothesis testing using a two-step Benjamini−
Hochberg procedure that controlled for the false discovery rate.23 The
relative protein abundances with adjusted p values ≤ 0.05 and fold-
change (FC) values ≥ 1.5 were considered as signiﬁcant in at least one
of the studied groups. For graphical summaries and to evaluate the
relationships among the studied samples, we used principal
component analysis and Ward’s linkage hierarchical clustering. All
statistical analyses were performed with MStat software. The software
used for bioinformatics analyses were available at http://proteom.ibb.
waw.pl/index.en.html.
Comet Assay. The extent of DNA damage in individual cells was
established by single cell gel electrophoresis using the OxiSelect
Comet assay kit (Cell Biolabs, San Diego, CA, USA) according to the
manufacturer’s instructions. Brieﬂy, 1 × 105 MDA-MB231 cells were
seeded in 75 cm2 ﬂasks in control conditions or treated with either
8.45 μM JAHA, 2.5 μM etoposide (VP16), or a mixture of the two
compounds, for 48 h. At the end of incubation, mechanically detached
cells were centrifuged, washed, and resuspended at 1 × 105/mL
concentration in Ca++/Mg++-free PBS at 4 °C. The samples were
mixed with Comet agarose (1:10 ratio, v/v) and the mixture spread
onto the OxiSelect Comet slides and allowed to gel. The slides were
then incubated with lysis buﬀer (4 °C, 45 min in the dark) followed by
treatment with an alkaline solution (4 °C, 30 min in the dark) to allow
DNA relaxation and denaturation. The damaged DNA was separated
by the intact fraction by alkaline gel electrophoresis in an horizontal
chamber (15 V, 30 min) in TBE running buﬀer to detect both single-
stranded and double-stranded DNA breaks. At the end of the run, the
slides were immersed in cold 70% ethanol for 5 min, air-dried, stained
with Vista Green DNA Dye, observed with a Nikon Microphot SA
ﬂuorescence microscope, and image analysis performed with CASP
Version 1.2.3b1 software (Sourceforge, Diceholdings Inc., New York,
NY, USA). Samples were run in triplicate and cells were selected
randomly for the analysis per slide. DNA damage was estimated on the
basis of tail length (TL), tail moment (TM), olive tail moment
(OTM), and % tail DNA (% DNA). Statistical analysis of the data was
performed using Excel software.
■ RESULTS
To search for diﬀerentially expressed genes in MDA-MB231
cells exposed to 8.45 μM HDACis for 18, 24, and 48 h, DD-
PCR was performed on enriched mRNA samples isolated from
control and treated cell preparations, in the presence of
combinations of the arbitrary primers, as listed previously. After
PAGE and silver stain, a number of bands appeared diﬀerently
displayed in parallel control and treated samples, and they were
cut from the gel and submitted to further analysis. To this
Table 1. Sequence of Primers Used for PCR Ampliﬁcation
transcript
detected
product size
(bp) oligonucleotides
PKCε 249 5′-GATCAGAAGGTCACTGCAA-3′
5′-GTCGTCATGGAGGATGGACT-3′
PKCι 169 5′-TACGGCCAGGAGATACAACC-3′
5′-TCGGAGCTCCCAACAATATC-3
ERGIC-2 196 5′-GCCATGGAGTCTCTGGGATA-3′
5′-CCAAGTCTGAAACGACAGCA-3′
RAD50 215 5′-CTTGGATATGCGAGGACGAT-3′
5′-CCAGAAGCTGGAAGTTACGC-3′
NTRK-2 181 5′-AGCATGAGCACATCGTCAAG-3′
5′-ATATGCAGCATCTGCGACTG-3′
BIG-3 231 5′-CGCCCTGTCTCTAAAACTGC-3′
5′-CTGTCTGCGTTCATCAGCAT-3′
VDUP1 223 5′-TTGTTCTCCCCTTCTGCCAT-3′
5′-AGGGTTGGGCATCTTGATCA-3′
IDI1 206 5′-TTGGGCTGGATAAAACCCCT-3′
5′-ACACAGGCCTTTGTTGTTGT-3′
gelsolin 270 5′-TGTGATCGAAGAGGTTCCTG-3′
5′-GACCAGTAATCATCATCCCA-3′
β-actin 51 5′-AGGCACCAGGGCGTGAT-3′
5′-GCCCACATAGGAATCCTTCTGAC-3′
GAPDH 414 5′-CATGGAGGAGGCTGGGGCTC-3′
5′-CACTGACACGTTGGCAGTGG-3′
Figure 1. Quantitative real-time PCR analysis of the transcript levels of RAD-50, NTRK2, BIG-3, PKCε, PKCι, and ERGIC-2 in MDA-MB231 cells
exposed to either 8.45 μM (A) JAHA or (B) SAHA for 24 h (RAD-50 and NTRK2) or 48 h (BIG-3, PKCε, PKCι, and ERGIC-2). Beta-actin was
used as an internal control. Values are the mean ± s.e.m. of two quadruplicate experiments. ∗ indicates p < 0.01 (student’s t test).
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purpose, the cDNA contained in the bands was puriﬁed,
reampliﬁed until purity and adequate yield, and then the
material was submitted to sequencing. Following BLAST
analysis, homology was found between six DD-bands and
portions of cDNAs of the following genes: (i) Neurotrophic
tyrosine kinase, receptor, type 2 (NTRK-2 a.k.a. TRKB,
NM_001018064.1), and (ii) RAD50 DNA repair protein
(NM_005732.3) both in 24 h-exposure preparations; (iii)
Brefeldine A-inhibited guanine nucleotide-exchange protein 3
(BIG-3, NM_020340.3), (iv) Protein kinase C epsilon (PKCε,
NM_005400.2), (v) Protein kinase C iota (PKCι;
NM_002740.5), (vi) Endoplasmic reticulum−Golgi intermedi-
ate compartment 2KDa protein (ERGIC-2, NM_016570.2), all
in 48 h exposure preparations.
Real time PCR assays were carried out to validate the DD-
PCR data since it is known that the technique may give false
positive results; in addition, to conﬁrm the speciﬁcity of the
HDACi-linked gene signatures, the expression of the genes
diﬀerentially displayed in case of either conditions of exposure
was cross-checked also in parallel control- and treated cell
preparations obtained after exposure to the other inhibitor. As
shown in Figure 1, JAHA at 8.45 μM concentration
prominently induced the expression of RAD50 and NTRK-2
genes after 24 h of treatment, while it reduced the expression of
PKCε after 48 h of treatment; on the other hand, the data
obtained with SAHA at the same concentration show a clear
reduction in the expression levels of BIG-3, PKCι, and ERGIC-2
genes after 48 h of treatment. Noteworthy, the cross-check test
demonstrated a drastic down-regulation of PKCε also in MDA-
MB231 cells treated for 48 h with SAHA. No signiﬁcant change
was found in the expression levels of RAD50 and NTRK2 in
SAHA-exposed cells and of BIG-3, PKCι, and ERGIC-2 in
JAHA-exposed cells.
Previous literature data4 reported that SAHA-exposed MDA-
MB231 cells developed up-regulation of some genes associated
with diﬀerentiation and/or growth inhibition, that is, those
encoding for gelsolin, isopentenyl-diphosphate delta isomerase-
1 (IDI1), and 1,25-dihydroxyvitamin D-3 up-regulated protein-
1 (VDUP1). To extend the comparative evaluation of the
molecular eﬀects of SAHA and JAHA inhibitors on MDA-
MB231 cells, we checked by real time PCR the eﬀects of MDA-
MB231 cell treatment with 8.45 μM JAHA for 48 h on the
expression levels of the same genes identiﬁed as up-regulated in
SAHA-treated cells. The results obtained show a similarity of
action of SAHA and JAHA on the expression levels of the genes
examined (Figure 2).
To expand the search of JAHA-associated signatures at the
protein level, proteomic analyses were performed and showed a
diﬀerential expression of 11 proteins (six, one, and four
associated to 18, 24, and 48 h of treatment with JAHA at 8.45
μM, respectively). As shown in Table 2, of the six proteins
associated to 18 h-treatment, four were down-regulated (i.e.,
Neuroblast diﬀerentiation-associated protein AHNAK protein,
High mobility group protein B2, Cystatin-B, High mobility
group protein B1) and two were up-regulated (i.e., Ribosome-
binding protein 1, Glutaredoxin-1) in treated samples. A single
up-regulated protein (i.e., Hematological and neurological
expressed 1 protein a.k.a. HN1) was found in cells treated
with JAHA for 24 h, and four up-regulated proteins in cells
treated with JAHA for 48 h (i.e., Prelamin-A/C, Ribosome-
binding protein 1, Sulﬁredoxin-1, Histone H1.0).
Twenty-two proteins appeared to be diﬀerentially expressed
in cells treated with SAHA at the same concentration (16, 5,
and 1, respectively, associated to 18, 24, and 48 h-treatment).
Of the 16 proteins identiﬁed at 18 h-treatment, six were down-
regulated (i.e., Reticulocalbin-1, Microtubule-associated protein
1B, Caprin-1, Spectrin α chain nonerythrocytic 1, Integrin β1,
Myristoylated alanine-rich C-kinase substrate), whereas the
other ones were up-regulated in the treated samples (i.e.,
Histone H1.0, Neuroblast diﬀerentiation-associated protein
AHNAK, Hematological and neurological expressed protein 1
a.k.a. HN1, Nucleolar and coiled-body phosphoprotein 1,
Nucleolin, Eukaryotic translation initiation factor 4H, 78 kDa
Glucose-regulated protein, Histidine triad nucleotide-binding
protein 2 mitochondrial, Na+/H+ exchange regulatory cofactor
NHE-RF1, Nonerythrocytic spectrin alpha chain 1, Integrin β1,
Heterogeneous nuclear ribonucleoproteins A2/B1). Of the ﬁve
proteins associated to 24 h-treatment, two were down-regulated
(i.e., Neuroblast diﬀerentiation-associated protein AHNAK,
Nicotinamide phosphoribosyltransferase) and three were up-
regulated (i.e., Na+/H+ exchange regulatory cofactor NHE-
RF1, Histone H1, 78 kDa Glucose-regulated protein). Finally, a
single protein was identiﬁed as down-regulated (Neuroblast
diﬀerentiation-associated protein AHNAK) in the samples
treated with the inhibitor for 48 h (Table 3).
The ﬁnding that exposure to JAHA induced the selective up-
regulation of molecular signatures linked to the processes of
DNA repair and response to oxidative stress, such as NTRK-2,
RAD50, sulﬁredoxin-1, and glutaredoxin-1, prompted to check
the related “in cellulo” eﬀect by examining whether the
presence of this HDACi could reverse the production of DNA
lesions induced by the topoisomerase IIα inhibitor VP16. The
genotoxic eﬀect of JAHA was assessed in MDA-MB231 breast
cancer cells using Comet assay. The panel in Figure 3 show the
very low level of DNA damage in control and 8.45 μM JAHA-
treated cells in contrast to 2.5 μM VP16-treated cells, as shown
by the mean DNA tail moment indicative of persistent double-
and single-strand breaks. Interestingly, DNA damage induced
by the latter was reduced by 50% when cells were coexposed to
8.45 μM JAHA and 2.5 μM VP16, as displayed by the decrease
of the DNA tail moment. Although, as compared to the basal
level of control cells, the total DNA damage appeared not to be
entirely reversible by VP16/JAHA cotreatment, nevertheless
this result conﬁrms that the DNA repair system was eﬃciently
switched-on in the presence of the HDACi, as suggested by
Figure 2. Quantitative real-time PCR analysis of the transcript levels of
gelsolin, IDI1, and VDPU1 in MDA-MB231 cells exposed to 8.45 μM
JAHA for 48 h. Beta-actin was used as an internal control. Values are
the mean ± s.e.m. of two quadruplicate experiments. ∗ indicates p <
0.01 (student’s t test).
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some of the revealed molecular signatures associated with
exposure of MDA-MB231 breast cancer cells to JAHA.
■ DISCUSSION
Breast tumor is a widely spread neoplastic histotype accounting
for about 20% of all cancers in women; about 15% of breast
cancers are TNBC and the lack of receptors for estrogens,
progesterone, and epidermal growth factor renders neoplastic
cells highly aggressive and endowed with a higher malignant
potential than other breast tumor subtypes (e.g., ref 24). Since
the pharmacological options for treating TNBC are limited,
there has been great interest in testing novel drugs or analogues
of pre-existing drugs counteracting TNBC cell growth, which,
on the other hand, necessitates a comprehensive biological
characterization. The eﬀects of the HDACi JAHA on aspects of
the biology of TNBC MDA-MB231 cells, such as survival, cell
cycle, mitochondrial activity, autophagy, apoptosis, and signal
transduction, have been the object of previous publications.16,25
Since it is widely acknowledged that multiplatform classiﬁcation
of breast cancers is based on genomic sequencing, gene
expression proﬁling, and proteomics, the present study was
focused on the evaluation of some molecular aspects of the
eﬀects exerted by JAHA on this cell line, also comparing with
those related to exposure to the parental HDACi SAHA.
For this reason, to supplement the catalogue of JAHA- (and
in parallel SAHA-) dependent genes and search for putative
molecular markers linked to the lethal action of JAHA, cDNA
samples obtained from enriched mRNA preparations of MDA-
Table 2. Diﬀerentially-Expressed Proteins Identiﬁed in MDA-MB231 Cells Cultured in Control Conditions and Exposed to 8.45
μM JAHA for 18, 24, and 48 h
accession no. protein Q value ratio (control/treated) fold change peptides
18 h
Q09666 Neuroblast diﬀerentiation-associated protein AHNAK 0.00079 1.35 1.35 276
P26583 High mobility group protein B2 0.00158 2.44 2.44 12
P04080 Cystatin-B (a.k.a Steﬁn-B) 0.02422 2.94 2.94 7
Q9P2E9 Ribosome-binding protein 1 (RRBP1) 0.02587 0.61 1.64 22
P09429 High mobility group protein B1 0.08112 2.70 2.70 11
P35754 Glutaredoxin-1 0.08978 0.48 2.09 5
24 h
Q9UK76 Hematological and neurological expressed 1 protein (HN1) 0.02226 0.44 2.26 10
48 h
P02545 Prelamin-A/C 0.00075 0.5 2.00 36
Q9P2E9 Ribosome-binding protein 1 (RRBP1) 0.01057 0.42 2.36 24
Q9BYN0 Sulﬁredoxin-1 0.04155 0.12 8.55 3
P07305 Histone H1.0 0.04578 0.20 5.05 6
Table 3. Diﬀerentially-Expressed Proteins Identiﬁed in MDA-MB231 Cells Cultured in Control Conditions and Exposed to 8.45
μM SAHA for 18, 24, and 48 h
accession no. protein Q value
ratio
(control/treated) fold change peptides
18h
P07305 Histone H1.0 0.00035 0.11 9.03 6
Q09666 Neuroblast diﬀerentiation-associated protein AHNAK 0.00035 1.41 1.41 257
Q9UK76 Hematological and neurological expressed 1 protein (HN1) 0.00280 0.47 2.13 10
Q15293 Reticulocalbin-1 0.00469 2.60 2.60 13
Q14978 Nucleolar and coiled-body phosphoprotein 1 0.00489 0.54 1.85 17
P19338 Nucleolin 0.00545 0.51 1.96 28
Q15056 Eukaryotic translation initiation factor 4H 0.00559 0.49 2.04 7
P46821 Microtubule-associated protein 1B 0.01389 2.03 2.03 14
Q14444 Caprin-1 0.01565 1.75 1.75 11
P11021 78 kDa glucose-regulated protein 0.01623 0.64 1.56 35
Q9BX68 Histidine triad nucleotide-binding protein 2, mitochondrial 0.01679 0.20 4.97 3
O14745 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 0.01776 0.37 2.71 4
Q13813 Spectrin alpha chain, nonerythrocytic 1 0.01849 1.51 1.51 36
P05556 Integrin β1 0.01877 1.67 1.67 10
P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 0.02038 0.55 1.81 14
P29966 Myristoylated alanine-rich C-kinase substrate 0.05348 1.98 1.98 10
24 h
Q09666 Neuroblast diﬀerentiation-associated protein AHNAK 0.00072 1.53 1.53 267
O14745 Na+/H+ exchange regulatory cofactor NHE-RF1 0.00502 0.26 3.79 4
P07305 Histone H1.0 0.01815 0.54 1.85 6
P11021 78 kDa glucose-regulated protein 0.03586 0.55 1.83 35
P43490 Nicotinamide phosphoribosyltransferase 0.05941 3.04 3.04 9
48 h
Q09666 Neuroblast diﬀerentiation-associated protein AHNAK 0.08576 2.26 2.26 254
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MB231 cells, both control and treated with the HDACis, were
submitted to DD-PCR assay and the results obtained were
conﬁrmed by real time-PCR assay. In parallel, protein extracts
from control and exposed cells were comparatively studied via
mass spectrometry and bioinformatics. The results obtained
indicate that under the same experimental conditions JAHA
and SAHA, although sharing some common aspects, induce a
diversiﬁed molecular reprogramming and allow one to draw the
following conclusions.
Exposure of cells to JAHA appeared to selectively trigger an
early and approximately four-fold overexpression of two
oxidative-stress related genes, that is, NTRK-2 and RAD-50.
The former encodes for a member of the tropomyosin-related
kinase family of neurotrophin receptors, which is up-regulated
in several human cancers, including TNBC, where it was found
to be involved in epithelial-mesenchymal transition, anoikis
resistance, and metastatic spread.26,27 In addition, a number of
studies performed on nerve and choriocarcinoma cell models
have demonstrated its powerful role in repair of oxidative DNA
damage and related inhibition of apoptosis. In particular, in rat
cortical neurons the NTRK-2 protective activity was found to
be accomplished via PI3K, pAKT, pCREB, and the expression
of APE1 (apurinic/apyrimidinic endonuclease-1), a key
component of the base excision DNA repair pathway.28,29
RAD-50 is known to participate with MRE11 and NBS1 to the
formation of the MRN complex, which coordinates the repair
of DNA double strand breaks in the nucleus.30 The inability of
SAHA to trigger RAD50 up-regulation was demonstrated also
in prostate cancer cells by Lee et al.,31 thereby further
conﬁrming that this is a JAHA-selective gene signature.
Evidence of JAHA’s role as antioxidative stress compound
emerged also from proteomic analyses demonstrating the
speciﬁc accumulation of glutaredoxin-1, cystatin-B, and, more
prominently and at a later time, sulﬁredoxin-1. The latter one is
an ATP-dependent cytoprotective antioxidant enzyme known
to catalyze peroxiredoxin reactivation and deglutathionylation
of glutathionylated proteins in several cytotypes exposed to
diversiﬁed chemical and biological stimuli that elicit the
production of reactive oxygen species.32 Glutaredoxin-1
catalyzes the reversible reduction of glutathione-protein mixed
disulﬁdes and is implicated in DNA repair and mitochondrial
DNA synthesis, thereby highly contributing to the antioxidant
cellular defense system.33 Cystatin-B is an inhibitor of
lysosomal cysteine cathepsin that has been proven to protect
mouse mammary tumor cells from oxidative stress and
consequent death.34 The ability of JAHA to reverse DNA
damage in cultured cells, at least in part, was demonstrated by a
Comet assay in JAHA/VP16 cotreatment experiments thereby
further substantiating that there is a correlation between the
increase of the molecular signatures involved in DNA repair
mechanisms and the peculiar ability of JAHA to reduce DNA
damage, through a molecular mechanism, which is still to be
determined. Noteworthy, this ﬁnding is contrary to what has
been described as a general aspect of HDACis,35 that is, the
inhibition of diﬀerent aspects of DNA repair including the
interference with coordination of ataxia-telangiectasia and
Rad3-related (ATR) activation and signaling, which is down-
stream Rad50 phosphorylation;36 this peculiar property of
JAHA seems truly interesting since it is uncommon but
beneﬁcial to ﬁnd a HDACi that simultaneously increases DNA
repair. Other speciﬁc JAHA signatures are represented by the
early down-regulation of the high mobility group proteins and
the up-regulation of RRBP1 that continues also in later time
coupled with the late up-regulation of prelamin A/C. The ﬁrst
ones are architectural transcription factors, and a miRNA-
triggered decrease of the amount of high mobility group
protein-B1 has been proven to impair MDA-MB231 cell cycle
progression and render these and other mammalian cytotypes
sensitive to a number of diversiﬁed death stimuli.37,38
Noteworthy, high mobility group proteins-B1 and -B2 are
known to play a DNA damage-sensing role and induce
phosphorylation of p53 as a response;39 therefore, the decrease
of the intracellular amount of these chromatin-associated
factors may be responsible, at least in part, of the previously
observed lack of apoptosis induction after cell exposure to
JAHA.25 On the other hand, apoptosis restraining could also
result from constant RRBP1 accumulation; this ribosome-
binding factor is associated with unfolded protein response in
the endoplasmic reticulum and its up-regulation has been found
to render lung cancer cells more resistant to the stress and to
alleviate apoptosis.40 Accumulation of prelamin A-C is
indicative of impairment of protein farnesylation which is a
prerequisite for its processing.41 It is known that farnesylated
species are cytotoxic, and in particular the accumulation of
prelamin A in ﬁbroblasts by siRNA transfection has been shown
to increase the levels of reactive oxygen species, aﬀect
mitochondrial respiration, and alter the expression of the
genes encoding detoxifying enzymes.42 In addition, it is worth
mentioning that farnesylation represents a maturation step for
Ras GTPase,43 and therefore, if JAHA determines in some way
Figure 3. (A) Representative micrographs of cell comets obtained from MDA-MB231 TNBC cells stained with Vista Green DNA Dye, observed
with a Nikon Microphot SA ﬂuorescence microscope: (a) control cells, (b) cells treated with 2.5 μM VP16 for 48 h, (c) cells treated with 8.45 μM
JAHA for 48 h, and (d) cells cotreated with 8.45 μM JAHA and 2.5 μM VP16 for 48 h. Microscopic magniﬁcation = 400×. (B) Histograms showing
the olive tail moment of the scored cells exposed to VP16, JAHA, and VP16/JAHA, as compared to control (n = 60 for each experimental
condition). Values are the mean ± s.e.m. of the results obtained. ∗ indicates p < 0.05 (student’s t test).
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the inhibition of farnesyltransferase activity as suggested by
accumulation of prelamin, it may exert its lethal eﬀect by also
targeting other substrates that play pivotal roles in the control
of cell survival and growth.
A number of molecular signatures were shared between
JAHA and SAHA. DD-PCR experiments demonstrated that the
two HDACis were able to induce a late PKCε down-regulation.
It is known that the down-regulation of this protein in MDA-
MB231 cells accounts for a reduced transcriptional activity of
NF-κB due to a signiﬁcant inhibition of nuclear translocation of
p65. This may lead to the alteration of the expression of genes
involved in cell survival and proliferation,44 which may be one
of the aspects involved in the already-observed perturbation of
MDA-MB231 cell cycle by JAHA,25 and expands the list of
shared gene signatures associated with diﬀerentiation or growth
inhibition, such as gelsolin, IDI1, and VDUP1. From proteomic
analyses, it appeared that JAHA and SAHA shared also a
decrease of the amount of the neuroblast diﬀerentiation-
associated protein AHNAK, more prolonged in the presence of
SAHA, and the increase of the amount of histone H1.0, earlier
in the presence of SAHA, and of HN1. Also histone H1.0 and
HN1 represent growth-associated factors. It is already known
that histone H1.0 gene expression is sensitive to the state of
chromatin acetylation, and in particular to the inhibition of
HDAc, as found for trichostatin A-treated mouse mammary
tumor cells.45 An immunohistochemical study on breast cancer
specimens of diﬀerent histological grading has strongly
suggested that histone H1.0 expression is linked to a
prolongation of cell intermitotic period irrespective of cell
malignant potential, thereby representing a marker of a low
proliferative activity.46 On the other hand, HN1, which is an
interaction partner of the inactive GSK3β/β-catenin/APC
complex contributing to ubiquitin-dependent proteasomal
degradation of β-catenin, when overexpressed in prostate
cancer cells have been shown to trigger their accumulation at
G2/M checkpoint, and to reduce the proliferation rate.
47 These
literature data are consistent with our previous results25
demonstrating cell cycle perturbation and a delay in G2/M
transition in MDA-MB231 cells exposed to JAHA. Various are
the intracellular roles played by the giant AHNAK protein in
very diverse biological processes.48 In breast cancer, this protein
was found to be localized in lipid rafts thus suggesting its
involvement in signaling pathways also linked with the
reorganization of actin submembraneous network.49 In
particular, when AHNAK was overexpressed in TNBC cell
lines, such as MDA-MB231, a marked inhibition of ERK
phosphorylation was observed; therefore, it is conceivable that
JAHA-mediated AHNAK down-regulation in this cell line may
be at least in part responsible of the observed early reduction of
the amount of pERK in MDA-MB231 wells exposed to JAHA,
as reported by Librizzi et al.16
A number of genes and, more prominently, protein
signatures, involved in diﬀerent biological events have been
found associated only to SAHA-, and not JAHA-, treatment
under the same experimental conditions. Thus, as opposed to
SAHA, JAHA did not appear to be active on the control of
speciﬁc enzyme activities via (i) the down-regulation of the
expression of BIG-3 encoding for an A-kinase anchoring
protein,50 and of PKCι whose depletion have been proven to
restrain TNBC growth and address cells to senescence,51,52 (ii)
the increase of accumulation of eukaryotic translation initiation
factor 4H, an activator of the RNA helicase eIF4A,53 and (iii)
the decrease of the amount of nicotinamide phosphoribosyl-
transferase, whose inhibition was found to suppress breast
tumor growth in vivo in a xenograft model.54 Other biological
mediators whose expression/accumulation was aﬀected by
SAHA, but not JAHA, are (i) the proliferation- and cell cycle-
aﬀecting factors ERGIC-2,55 myristoylated alanine-rich C-
kinase substrate,56 nucleolin,57 nucleolar and coiled-body
phosphoprotein 1,58 reticulocalbin-1,59 spectrin alpha chain,
nonerythrocytic 1,60 and caprin-1,61 (ii) the autophagy marker
microtubule-associated protein 1B,62 (iii) the endoplasmic
reticulum chaperone 78 kDa glucose-regulated protein,63 and
(iv) signaling molecules such as the extracellular matrix
receptor subunit integrin β1,64 the ERK-activating factor
heterogeneous nuclear ribonucleoproteins A2/B1,65 the
EGFR regulator Na(+)/H(+) exchange regulatory cofactor
NHE-RF1,66 and the inhibitor of Wnt/β-catenin pathway
histidine triad nucleotide-binding protein 2.67
In summary, in this study we have established a number of
molecular signatures in response to the HDACi JAHA in a
TNBC cell model, and although this compound is closely
related to the parental molecule SAHA, we have revealed some
substantial diﬀerences in the biomarkers of drug responses. In
contrast to the more numerous and diversiﬁed changes induced
by SAHA, JAHA displays a more selective impact on the
expression of molecular signatures by increasing the expression
of some molecular signatures involved in antioxidant activity
and DNA repair. This speciﬁc property will represent a
challenge, which must be taken into account in a future
consideration of this molecule as an anticancer drug. Literature
data have already reported the eﬀect of SAHA or other
HDACis on only ﬁve among the molecular signatures identiﬁed
in this study, that is, 78 kDa glucose-regulated protein, integrin
β1, NHE-RF1, reticulocalbin-1, and histone H1.0.68−72 There-
fore, our work also contributes to expand the list of molecular
signature responsive to cell exposure to these enzyme
inhibitors. On the basis of the present exploratory study,
further work using global gene expression and proteomic
proﬁling protocols will allow a further understanding of the
selective molecular response associated with their mechanisms
of action, and to deﬁne key client transcripts and proteins for
either speciﬁc compound with potential clinical signiﬁcance
minimizing the problematic eﬀects and emphasizing the
therapeutic ones.
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concentration; pERK, phosphorylated extracellular signal-
related kinase; DNMT, DNA methyltransferase; PCR,
polymerase chain reaction; EDTA, ethylenediaminetetraacetic
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mean; NTRK-2, neurotrophic tyrosine kinase, receptor, type 2;
BIG-3, brefeldine A-inhibited guanine nucleotide-exchange
protein 3; PKCε, protein kinase C epsilon; PKCι, protein
kinase C iota; ERGIC-2, endoplasmic reticulum-Golgi inter-
mediate compartment 2KDa protein; IDI1, isopentenyl-
diphosphate delta isomerase-1; VDUP1, 1,25-dihydroxyvitamin
D-3 up-regulated protein-1; RRBP1, ribosome-binding protein
1; HN1, hematological and neurological expressed 1 protein;
NHE-RF1, Na(+)/H(+) exchange regulatory cofactor; PI3K,
phosphatidylinositol-4,5-bisphosphate 3-kinase; pCREB, phos-
phorylated cyclic AMP response element binding; APE1,
apurinic/apyrimidinic endonuclease-1; MRN, Mre11-Rad50-
Nbs1; siRNA, short interfering RNA; GSK3β, glycogen
synthase kinase 3 beta; APC, adenomatous polyposis coli;
EGFR, epidermal growth factor receptor; ATR, ataxia-
telangiectasia and Rad3-related
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